SR
Therapeutic Areas
atai Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PCN-101 (R-ketamine) | Treatment-Resistant Depression (TRD) | Phase 2 |
| RL-007 | Cognitive Impairment Associated with Schizophrenia (CIAS) | Phase 2 |
| DMX-1002 (Ibogaine) | Opioid Use Disorder (OUD) | Phase 1/2a |
| GRX-917 (Deuterated Etifoxine) | Generalized Anxiety Disorder (GAD) | Phase 1 |
| VLS-01 (DMT) | Treatment-Resistant Depression (TRD) | Phase 1 |
| EMP-01 (MDMA derivative) | Post-Traumatic Stress Disorder (PTSD) | Preclinical |
| KUR-101 (Deuterated Mitragynine) | Opioid Use Disorder (OUD) | Preclinical |
| Salvianolic Acid B | Treatment-Resistant Depression (TRD) | Preclinical |
Leadership Team at atai Life Sciences
FB
Florian Brand
Co-Founder & Chief Executive Officer
SB
Stephen Bardin
Chief Financial Officer
MA
Michael Andree
Chief Operating Officer
GW
Gregory Weaver
Chief Financial Officer (former)
LB
Lance B. Baldo, M.D.
Chief Medical Officer
AS
Andrea Spezzi
Chief Marketing Officer & Head of Digital
CA
Christian Angermayer
Co-Founder & Chairman of the Board
SK
Sahil Kirpekar
Board Member
EA
Ernest A. Bates, M.D.
Board Member
JC
Jason C. Bartz, Ph.D.
Board Member, Scientific Advisory Board Chair